The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19
Open accessAbstract
“Fungi are the interface organisms between life and death.” -- Paul Stamets Mucormycosis is a potentially lethal, angioinvasive fungal infection predisposed by diabetes mellitus, corticosteroids and immunosuppressive drugs, primary or secondary immunodeficiency, hematological malignancies and hematological stem cell transplantation, solid organ malignancies and solid organ transplantation, iron overload, etc.[1] The increasing incidence of rhino-orbito-cerebral mucormycosis (ROCM) in the setting of COVID-19 in India and elsewhere has become a matter of immediate concern.[234] From the time that we first reported a series of six cases of ROCM in February 2020,[2] there has been an exponential increase in incidence in India, in sync with the soaring second wave of COVD-19.[56] ROCM being a rapidly progressive disease, even a slight delay in the diagnosis or appropriate management can have devastating implications on patient survival.[7] However, the outcome can be optimized by early diagnosis prompted by awareness of warning symptoms and signs and a high index of clinical suspicion, confirmation of diagnosis by appropriate modalities, and initiation of aggressive medical and surgical treatment by a multidisciplinary team.[17] This article aims to provide a succinct list of red flags to suspect ROCM, propose a working disease staging system to help choose an appropriate diagnostic modality and tailor therapy, describe an evidence-based management algorithm, and outline possible preventive measures. Red Flags of ROCM in the Setting of COVID-19 The COVID-19 care teams must be aware of the warning symptoms and signs of ROCM. If a patient currently under active treatment for COVID-19 or on follow-up after completion of treatment exhibits any of the symptoms and signs listed in Table 1, there should be a very high index of suspicion for ROCM, and an immediate ophthalmology and otorhinolaryngology consultation is warranted.[17] Explanation of early warning signs to patients and the family on discharge following treatment of COVID-19 and a carry-home list of warning symptoms may prompt them to seek early medical attention.Table 1: Warning symptoms and signs of rhino-orbito-cerebral mucormycosisDiagnosis of ROCM ROCM can be categorized as Possible, Probable, and Proven. A patient who has symptoms and signs of ROCM [Table 1] in the clinical setting of concurrent or recently (<6 weeks) treated COVID-19, diabetes mellitus, use of systemic corticosteroids and tocilizumab, mechanical ventilation, or supplemental oxygen is considered as Possible ROCM. When the clinical symptoms and signs are supported by diagnostic nasal endoscopy findings, or contrast-enhanced MRI or CT Scan, the patient is considered as Probable ROCM. Clinico-radiological features, coupled with microbiological confirmation on direct microscopy or culture or histopathology with special stains or molecular diagnostics are essential to categorize a patient as Proven ROCM. Table 2 lists specifications and criteria for microbiological, histopathological, molecular, and radiological diagnosis of ROCM.Table 2: Supportive evidence for the diagnosis of rhino-orbito-cerebral mucormycosis (ROCM)[7 8]Staging of ROCM There is no good staging system to categorize the disease severity of ROCM and stratify the diagnostic modalities and management. As the critical care teams start receiving and caring for increasing number of ROCM patients in the setting of COVID-19, a working staging system may help triage these patients and customize their care. The proposed staging system is simple and follows the general anatomical progression of ROCM from the point of entry (nasal mucosa) on to the paranasal sinuses, orbit and brain, and severity in each of these anatomical locations [Fig. 1]. There is an attempt to plug in the symptoms, signs, and preferred diagnostic tools for each of these stages. The next logical step could be to validate it, propose the preferred management for each stage, and then correlate the outcomes.Figure 1: Proposed staging of Rhino-Orbito-Cerebral Mucormycosis with clinical symptoms and signs, evaluation and diagnosisLogical Management of ROCM Optimizing the outcome, minimizing the morbidity, and improving the survival in ROCM needs concerted action and rapid response by a multi-disciplinary team comprising of experts in diagnosis (radiology, microbiology, pathology, molecular biology), and medical (infectious disease, neurology, critical care) and surgical (otorhinolaryngology, ophthalmology, neurosurgery) care.[78] Evidence-based and clear management guidelines help synergize the management within the team. The European Confederation of Medical Mycology (ECMM) and the Mycoses Study Group Education and Research Consortium (MSG ERC) have issued comprehensive management guidelines.[7] Fig. 2 provides diagnostic and management algorithms with salient aspects of the elaborate ECMM-MSG ERC guidelines adapted to standard disease definitions and customized to
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
De Pauw, B., Walsh, T. J., Donnelly, J. P., Stevens, D. A., Edwards, J. E., Calandra, T., Pappas, P. G., Maertens, J., Lortholary, O., Kauffman, C. A., et al. (2008) · Clinical Infectious Diseases · doi:10.1086/588660 · Cited by 4,917
Cornely, O. A., Alastruey-Izquierdo, A., Arenz, D., Chen, S. C. A., Dannaoui, E., Hochhegger, B., Hoenigl, M., Jensen, H. E., Lagrou, K., Lewis, R. E., et al. (2019) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(19)30312-3 · Cited by 1,820
Epidemiology and Diagnosis of Mucormycosis: An Update
Skiada, A., Pavleas, I., & Drogari-Apiranthitou, M. (2020) · Journal of Fungi · doi:10.3390/jof6040265 · Cited by 687
Mucor in a Viral Land: A Tale of Two Pathogens
Sen, M., Lahane, S., Lahane, T. P., Parekh, R., & Honavar, S. G. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3774_20 · Cited by 387
Self-citationCOVID-19 and Eye: A Review of Ophthalmic Manifestations of COVID-19
Sen, M., Honavar, S. G., Sharma, N., & Sachdev, M. S. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_297_21 · Cited by 365
Self-citationCOVID-19 and orbital mucormycosis
Sarkar, S., Gokhale, T., Choudhury, S. S., & Deb, A. K. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_3763_20 · Cited by 263
Rise of the phoenix: Mucormycosis in COVID-19 times
Ravani, S. A., Agrawal, G. A., Leuva, P. A., Modi, P. H., & Amin, K. D. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_310_21 · Cited by 197
Sipsas, N. V., Gamaletsou, M. N., Anastasopoulou, A., & Kontoyiannis, D. P. (2018) · Journal of Fungi · doi:10.3390/jof4030090 · Cited by 183
Cited by
Sen, M., Honavar, S. G., Bansal, R., Sengupta, S., Rao, R., Kim, U., Sharma, M., Sachdev, M., Grover, A. K., Surve, A., et al. (2021) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1565_21 · Cited by 418
Self-citation
Metadata
- Authors
- Honavar, S. G.
- Venue
- Indian Journal of Ophthalmology
- Published
- 2021-06
- Volume
- 69
- Issue
- 6
- Pages
- 1361-1365
- ISSN
- 0301-4738 (ISSN-L)
- 1998-3689
- OpenAlex
- W3163927982
- Cited by
- 309
- References
- 8
- FWCI
- 20.21
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19. https://app.cochat.ai/papers/10.4103/ijo.ijo_1165_21
- The paper
- Honavar, S. G. (2021). Code Mucor: Guidelines for the Diagnosis, Staging and Management of Rhino-Orbito-Cerebral Mucormycosis in the Setting of COVID-19. Indian Journal of Ophthalmology. https://doi.org/10.4103/ijo.ijo_1165_21
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.